EUROMACS机械循环支持注册登记第二次报告
该报告由EACTS支持的EUROMACS注册登记发布,汇总2011至2016年52家医院2947例机械循环支持植入数据;成人连续流左心室辅助装置患者1年生存率为69%(95%CI 66-71%),并报告器械故障、大出血、大感染及神经事件发生率。
要点
- EUROMACS第二次报告纳入52家医院2947例机械循环支持植入数据。
- 成人连续流左心室辅助装置患者1年生存率为69%(95%CI 66-71%)。
- 植入后3个月内器械故障、大出血、大感染及神经事件发生率分别为每100患者月3.56、6.45、6.18和3.03。
核心结论
- 与首次报告相比,参与医院从21家增至52家(+148%),注册植入数从825例增至2947例(+257%)。
- 参与医院增加促使通过数据输入控制、现场审计和统计分析加强质量控制。
研究设计与样本
- EUROMACS为EACTS支持的注册登记,参与医院提交机械循环支持植入的术前、围术期及长期术后数据。
- 分析2011年1月1日至2016年12月31日所有植入数据,共52家医院、2681例患者、2947例注册植入。
主要发现
- 成人(>17岁)连续流左心室辅助装置患者平均随访391天,植入后1年生存率为69%(95%CI 66-71%)。
- 患者平均观察12个月(中位7个月,范围0-70个月)。
- 植入后3个月内,器械故障发生率为每100患者月3.56。
- 植入后3个月内,大出血发生率为每100患者月6.45。
- 植入后3个月内,大感染发生率为每100患者月6.18。
临床怎么用
- 报告提供的生存率与不良事件发生率可用于机械循环支持患者的风险沟通与随访监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) was founded in Berlin, Germany. EUROMACS is supported fully by the European Association for Cardio-Thoracic Surgery (EACTS) and, since 2014, has functioned as a committee of the EACTS. The purpose of having the EUROMACS as a part of the EACTS is to accumulate clinical data related to long-term mechanical circulatory support for scientific purposes and to publish annual reports. METHODS: Participating hospitals contributed surgical and cardiological pre-, peri- and long-term postoperative data of mechanical circulatory support implants to the registry. Data for all implants performed from 1 January 2011 to 31 December 2016 were analysed. Several auditing methods were used to monitor the quality of the data. Data could be provided for in-depth studies, and custom data could be provided at the request of clinicians and scientists. This report includes updates of patient characteristics, implant frequency, mortality rates and adverse events. RESULTS: Fifty-two hospitals participated in the registry. This report is based on 2947 registered implants in 2681 patients. Survival of adult patients (>17 years of age) with continuous-flow left ventricular assist devices with a mean follow-up of 391 days was 69% (95% confidence interval 66-71%) 1 year after implantation. On average, patients were observed for 12 months (median 7 months, range 0-70 months). When we investigated for adverse events, we found an overall event rate per 100 patient-months of 3.56 for device malfunction, 6.45 for major bleeding, 6.18 for major infection and 3.03 for neurological events within the first 3 months after implantation. CONCLUSIONS: Compared to the first EUROMACS report, the number of participating hospitals increased from 21 to 52 (+148%), whereas the number of registered implants more than tripled from 825 to 2947 (+257%). The increase in the number of participating hospitals led us to increase the quality control measures through data input control, on-site audits and statistical analyses.
引用
- de By TMMH, Mohacsi P, Gahl B, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg. 2018. PMID: 29029117. doi:10.1093/ejcts/ezx320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。